<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#Cover" roleURI="http://pharmacyte.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#NatureOfBusiness" roleURI="http://pharmacyte.com/role/NatureOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#LiquidityAndOtherUncertainties" roleURI="http://pharmacyte.com/role/LiquidityAndOtherUncertainties" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#InvestmentInDebtAndEquitySecurities" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecurities" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#AccruedExpenses" roleURI="http://pharmacyte.com/role/AccruedExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#StockOptionsAndWarrants" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#OtherRelatedPartyTransactions" roleURI="http://pharmacyte.com/role/OtherRelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#CommitmentsAndContingencies" roleURI="http://pharmacyte.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#EarningsPerShare" roleURI="http://pharmacyte.com/role/EarningsPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#PreferredStock" roleURI="http://pharmacyte.com/role/PreferredStock" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#FairValueMeasurements" roleURI="http://pharmacyte.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#InvestmentInDebtAndEquitySecuritiesTables" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#AccruedExpensesTables" roleURI="http://pharmacyte.com/role/AccruedExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#StockOptionsAndWarrantsTables" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#EarningsPerShareTables" roleURI="http://pharmacyte.com/role/EarningsPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#FairValueMeasurementsTables" roleURI="http://pharmacyte.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#LiquidityAndOtherUncertaintiesDetailsNarrative" roleURI="http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#InvestmentInDebtAndEquitySecuritiesDetailsNarrative" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#AccruedExpensesDetails" roleURI="http://pharmacyte.com/role/AccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#StockOptionsAndWarrantsDetails-OptionActivity" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#StockOptionsAndWarrantsDetails-WarrantActivity" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#StockOptionsAndWarrantsDetailsNarrative" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#OtherRelatedPartyTransactionsDetailsNarrative" roleURI="http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#EarningsPerShareDetails-EarningsLossPerShare" roleURI="http://pharmacyte.com/role/EarningsPerShareDetails-EarningsLossPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#EarningsPerShareDetails-DilutedShares" roleURI="http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#PreferredStockDetailsNarrative" roleURI="http://pharmacyte.com/role/PreferredStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#FairValueMeasurementsDetails-FairValue" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260731.xsd#FairValueMeasurementsDetails-FairValuesOfFinancialInstruments" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsReceivable" xlink:label="loc_us-gaapDividendsReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDividendsReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_InvestmentInPreferredStockQclsCurrent" xlink:label="loc_PMCBInvestmentInPreferredStockQclsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_PMCBInvestmentInPreferredStockQclsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_WarrantAssetNoncurrent" xlink:label="loc_PMCBWarrantAssetNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_PMCBWarrantAssetNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_WarrantAssetFemasys" xlink:label="loc_PMCBWarrantAssetFemasys" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_PMCBWarrantAssetFemasys" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDividendsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_WarrantLiabilitiesNoncurrent" xlink:label="loc_PMCBWarrantLiabilitiesNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilities" xlink:to="loc_PMCBWarrantLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_TotalTemporaryEquity" xlink:label="loc_PMCBTotalTemporaryEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PMCBTotalTemporaryEquity" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_ContingentlyRedeemableWarrants" xlink:label="loc_PMCBContingentlyRedeemableWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PMCBTotalTemporaryEquity" xlink:to="loc_PMCBContingentlyRedeemableWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="loc_us-gaapTreasuryStockCommonValue" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockCommonValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_PMCBTotalTemporaryEquity" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendIncomeOperating" xlink:label="loc_us-gaapDividendIncomeOperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDividendIncomeOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_ChangeInFairValueOfWarrantLiability" xlink:label="loc_PMCBChangeInFairValueOfWarrantLiability" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBChangeInFairValueOfWarrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_PMCBChangeInFairValueOfDerivativeLiability" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBChangeInFairValueOfDerivativeLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_ChangeInFairValueOfConvertibleNoteReceivable" xlink:label="loc_PMCBChangeInFairValueOfConvertibleNoteReceivable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBChangeInFairValueOfConvertibleNoteReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:label="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_ChangeInFairValueOfInvestment" xlink:label="loc_PMCBChangeInFairValueOfInvestment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBChangeInFairValueOfInvestment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_ChangeInFairValueOfWarrantAsset" xlink:label="loc_PMCBChangeInFairValueOfWarrantAsset" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBChangeInFairValueOfWarrantAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_GainOnFairValueOfWarrantsWainwright" xlink:label="loc_PMCBGainOnFairValueOfWarrantsWainwright" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBGainOnFairValueOfWarrantsWainwright" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_us-gaapPreferredStockAccretionOfRedemptionDiscount" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockAccretionOfRedemptionDiscount" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS&apos; EQUITY (UNAUDITED)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_GainOnFairValueOfWarrants" xlink:label="loc_PMCBGainOnFairValueOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBGainOnFairValueOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_AdjustmentFromAccruedLiabilitiesToWarrantLiabilities" xlink:label="loc_PMCBAdjustmentFromAccruedLiabilitiesToWarrantLiabilities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBAdjustmentFromAccruedLiabilitiesToWarrantLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_StockbasedCompensationOptions" xlink:label="loc_PMCBStockbasedCompensationOptions" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBStockbasedCompensationOptions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_PMCBChangeInFairValueOfWarrantLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBChangeInFairValueOfWarrantLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_PMCBChangeInFairValueOfDerivativeLiability" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBChangeInFairValueOfDerivativeLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_ChangeInFairValueOfConvertibleNotesReceivable" xlink:label="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:label="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_ChangeInFairValueOfInvestmentQcls" xlink:label="loc_PMCBChangeInFairValueOfInvestmentQcls" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBChangeInFairValueOfInvestmentQcls" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_ChangeInFairValueOfWarrantsQcls" xlink:label="loc_PMCBChangeInFairValueOfWarrantsQcls" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBChangeInFairValueOfWarrantsQcls" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260731.xsd#PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends" xlink:label="loc_PMCBPaymentOfSeriesCConvertiblePreferredStockDividends" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PMCBPaymentOfSeriesCConvertiblePreferredStockDividends" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/NatureOfBusiness" xlink:title="999013 - Disclosure - NATURE OF BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/LiquidityAndOtherUncertainties" xlink:title="999014 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecurities" xlink:title="999016 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/AccruedExpenses" xlink:title="999017 - Disclosure - ACCRUED EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrants" xlink:title="999018 - Disclosure - STOCK OPTIONS AND WARRANTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/OtherRelatedPartyTransactions" xlink:title="999019 - Disclosure - OTHER RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CommitmentsAndContingencies" xlink:title="999020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShare" xlink:title="999021 - Disclosure - EARNINGS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/PreferredStock" xlink:title="999022 - Disclosure - PREFERRED STOCK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurements" xlink:title="999023 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables" xlink:title="999025 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/AccruedExpensesTables" xlink:title="999026 - Disclosure - ACCRUED EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsTables" xlink:title="999027 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShareTables" xlink:title="999028 - Disclosure - EARNINGS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsTables" xlink:title="999029 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative" xlink:title="999030 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants" xlink:title="999032 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities" xlink:title="999033 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants" xlink:title="999034 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants" xlink:title="999035 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative" xlink:title="999036 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/AccruedExpensesDetails" xlink:title="999037 - Disclosure - ACCRUED EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity" xlink:title="999038 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Option activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity" xlink:title="999039 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Warrant activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative" xlink:title="999040 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative" xlink:title="999041 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999042 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShareDetails-EarningsLossPerShare" xlink:title="999043 - Disclosure - EARNINGS PER SHARE (Details - Earnings (loss) per share)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares" xlink:title="999044 - Disclosure - EARNINGS PER SHARE (Details - Diluted shares)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/PreferredStockDetailsNarrative" xlink:title="999045 - Disclosure - PREFERRED STOCK (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue" xlink:title="999046 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair value)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability" xlink:title="999047 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability" xlink:title="999048 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments" xlink:title="999049 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)" />
</link:linkbase>
